445days since
World-Wide Lyme Disease Protest

Australian World Wide Lyme Disease Protest

Low Dose Naltrexone - LDN

This page on LDN has been put together by Sue as a result of going on LDN for Sarcoidosis. 

I've found that my pain levels have been massively reduced and much of my medication for pain management has been cut. This is a saving to the Government of today so I find it very hard to understand why this simple, effective drug with very little side effects and definitely no serious ones is so hard for people to obtain. 

The evidence for Low Dose Naltrexone is amazing and seems to be mounting rapidly. So one has to ask the question - WHY is this so unaccessable for a large proportion of the population?

LDN (Low Dose Naltrexone) - The Way it Works

LDN (Low Dose Naltrexone) - The Way it Works


LDN - The Way it Works....

Naltrexone, in a low dose (LDN) is believed to boost the endorphins that are required to regulate the immune system – as a result it slows down progression of diseases such as Cancer, Sarcoidosis, Lyme Disease, Crohn’s, Fibromyalgia, HIV/Aids, MS and a whole host of other related illnesses.


Until there’s a cure, there’s LDN


Dr Chris Steele MBE, shows his support for Low Dose Naltrexone (LDN) and the LDNNow campaign to get this drug available as front line treatment for autoimmune diseases and cancers


LDNNow - Dr Chris Steele MBE talks about Low Dose Naltrexone (LDN)


Web Links


To Learn about LDN go to http://www.lowdosenaltrexone.org/



http://www.ldnnow.co.uk/


http://www.ldnaware.org/


The Mary Bradley Show is a weekly Internet radio show about the health benefits of Low Dose Naltrexone (LDN) for all diseases based on a disturbed immune system.


Logo LDNscience.org


http://www.ldnscience.org/




http://www.ldners.org/


http://www.ldn-help.com/


Glasgow LDN Conference Info

o    LDN Conference report

o    LDN Conference presentations

o    LDN Conference interviews

o    Conference archive

LDN Links

o    LDN Videos

o    LDN Research

News

o    2nd European LDN conference, Glasgow 2010

o    The European LDN Conference videos

o    LDN Conference Venue information

o    Stanford Fibromyalgia study

o    LDN Dose Timing


Essential Health Clinic - LDN information


Information Sources

> You can go to more detailed information on these linked pages:

Clinical trials & papers about LDN

from fiikus

Traore AK, Thiero O, Dao S, et al. Single cohort study of the effect of low dose naltrexone on the evolution of immunological, virological and clinical state of HIV+ adults in Mali. J AIDS HIV Res. 2011 Oct;3(10):180-8. link

Traore AK, Thiero O, Dao S, et al. Impact of low dose naltrexone (LDN) on antiretroviral therapy (ART) treated HIV+ adults in Mali: A single blind randomized clinical trial. J AIDS HIV Res. 2011 Oct;3(10):189-98. link

[No authors listed]. Low-dose naltrexone: tricking the body to heal itself. Exp Biol Med (Maywood). 2011 Sep 1;236(9):vii-viii. PMID: 21991594 (link)

Frech T, Novak K, Revelo MP, et al. Low-dose naltrexone for pruritus in systemic sclerosis. Int J Rheumatol. 2011;2011:804296. PMID: 21918649

[No authors listed]. Low-dose naltrexone: harnessing the body's own chemistry to treat human ovarian cancer. Exp Biol Med (Maywood). 2011 Jul 1;236(7):viii. PMID: 21887861

Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Exp Biol Med (Maywood). 2011 Sep 1;236(9):1036-50. PMID: 21807817

Raknes G, Giverhaug T. [Low dosage naltrexone]. Tidsskr Nor Laegeforen. 2011 Aug 9;131(15):1415-6. PMID: 21844938

Holmøy T. [Research on low dosage naltrexone]. Tidsskr Nor Laegeforen. 2011 Jul 1;131(13-14):1277-8. PMID: 21725378

Raknes G, Giverhaug T. [Naltrexone--high expectations to low dosages]. Tidsskr Nor Laegeforen. 2011 May 6;131(8):844-6. PMID: 21556092

Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Exp Biol Med (Maywood). 2011 Jul 1;236(7):883-95. Epub 2011 Jun 17. PMID: 21685240

McLaughlin PJ, Stucki JK, Zagon IS. Modulation of the opioid growth factor ([Met(5) ]-enkephalin)-opioid growth factor receptor axis: Novel therapies for squamous cell carcinoma of the head and neck. Head Neck. Painossa 2011. PMID: 21584896

Raknes G, Giverhaug T. [Low dosage naltrexone]. Tidsskr Nor Laegeforen. 2011 Aug 9;131(15):1415-6. PMID: 21844938

Donahue RN, McLaughlin PJ, Zagon IS. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. Gynecol Oncol. 2011 Aug;122(2):382-8. PMID: 21531450

Smith JP, Bingaman SI, Ruggiero F, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. Dig Dis Sci. 2011 Jul;56(7):2088-97. PMID: 21380937

Hesselink JM, Kopsky DJ. Enhancing acupuncture by low dose naltrexone. Acupunct Med. 2011 Jun;29(2):127-30. PMID: 21415049

Rahn KA, McLaughlin PJ, Zagon IS. Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis. Brain Res. 2011 Mar 24;1381:243-53. PMID: 21256121

ALSUntangled Group. ALSUntangled No. 8: Low dose naltrexone for ALS. Amyotroph Lateral Scler. 2011 Jan;12(1):76-8. PMID: 21174518

Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, et al. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. 2010 Aug;16(8):964-9. PMID: 20534644

Shannon A, Alkhouri N, Mayacy S, et al. Low-dose naltrexone for treatment of duodenal Crohn's disease in a pediatric patient. Inflamm Bowel Dis. 2010 Sep;16(9):1457. PMID: 20014017

Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010 Aug;68(2):145-50. PMID: 20695007

Berkson BM, Rubin DM, Berkson AJ. Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases. PMID: 20042414

Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009 May-Jun;10(4):663-72. PMID: 19453963

Desjardins S, Doyen C, Contejean Y, et al. Treatment of a serious autistic disorder in a child with Naltrexone in an oral suspension form. Encephale. 2009 Apr;35(2):168-72.PMID: 19393386

Brown N, Panksepp J. Low-dose naltrexone for disease prevention and quality of life. Med Hypotheses. 2009 Mar;72(3):333-7. PMID: 19041189

Gironi M, Martinelli-Boneschi F, et al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult Scler. 2008 Sep;14(8):1076-83. PMID: 18728058

Patel PN. Low-dose naltrexone for treatment of multiple sclerosis: clinical trials are needed. Ann Pharmacother. 2007 Sep;41(9):1549-50. PMID: 17623758

Berkson BM, Rubin DM, Berkson AJ. Reversal of signs and symptoms of a B-cell lymphoma in a patient using only low-dose naltrexone. Integr Cancer Ther. 2007 Sep;6(3):293-6.PMID: 17761642

Mannelli P, Patkar AA, Peindl K, et al. Effectiveness of Low-Dose Naltrexone in the Post-Detoxification Treatment of Opioid Dependence. J Clin Psychopharmacol. 2007 Oct;27(5):468-74. PMID: 17873678

Smith JP, Stock H, Bingaman S, et al. Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol. 2007 Apr;102(4):820-8. PMID: 17222320

Good P. Low-dose naltrexone for multiple sclerosis and autism: does its benefit reveal a common cause? Med Hypotheses. 2006;67(3):671-2. PMID: 16759815

Berkson BM, Rubin DM, Berkson AJ. The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol. Integr Cancer Ther. 2006 Mar;5(1):83-9. PMID: 16484716

Agrawal YP. Low dose naltrexone therapy in multiple sclerosis. Med Hypotheses. 2005;64(4):721-4. PMID: 15694688

Bihari B. Efficacy of low dose naltrexone as an immune stabilizing agent for the treatment of HIV/AIDS [letter]. AIDS Patient Care. 1995 Feb;9(1):3. PMID: 11361353

Bouvard MP, Leboyer M, Launay JM, et al. Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. Psychiatry Res. 1995 Oct 16;58(3):191-201. PMID: 8570775

Bihari B, Drury F, Ragone V, et al. Low dose naltrexone in the treatment of AIDS: long term follow-up results. V International Conference on AIDS. Poster M. C.P. 62. Montreal, June 1989.

Bihari B, Drury F, Ragone V, et al. Low dose naltrexone in the treatment of AIDS. IV International Conference on AIDS. Poster 3056. Stockholm, June 1988. link

Other research and publications related to the subject (e.g. the mode of action of LDN)

Cancer

Sarkar DK, Zhang C, Murugan S, et al. Transplantation of {beta}-Endorphin Neurons into the Hypothalamus Promotes Immune Function and Restricts the Growth and Metastasis of Mammary Carcinoma. Cancer Res. 2011 Oct 1;71(19):6282-91. PMID: 21835894

Boehncke S, Hardt K, Schadendorf D, et al. Endogenous μ-opioid peptides modulate immune response towards malignant melanoma. Exp Dermatol. 2011 Jan;20(1):24-8. PMID: 20955200

Smith JP, Bingaman SI, Mauger DT, et al. Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer. Open Access J Clin Trials. 2010 Mar 1;2010(2):37-48. PMID: 20890374

Avella DM, Kimchi ET, Donahue RN, et al. The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer. Am J Physiol Regul Integr Comp Physiol. 2010 Feb;298(2):R459-66. PMID: 19923357

McLaughlin PJ, Zagon IS, Park SS, et al. Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis. PMID: 19835629

Zagon IS, Donahue RN, McLaughlin PJ. Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers.Am J Physiol Regul Integr Comp Physiol. 2009 Oct;297(4):R1154-61. PMID: 19675283

Donahue RN, McLaughlin PJ, Zagon IS. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis. Am J Physiol Regul Integr Comp Physiol. 2009 Jun;296(6):R1716-25. PMID: 19297547

McLaughlin PJ, Kreiner S, Morgan CR, et al. Prevention and delay in progression of human squamous cell carcinoma of the head and neck in nude mice by stable overexpression of the opioid growth factor receptor. Int J Oncol. 2008 Oct;33(4):751-7. PMID: 18813788

Zagon IS, Kreiner S, Heslop JJ, et al. Prevention and delay in progression of human pancreatic cancer by stable overexpression of the opioid growth factor receptor. Int J Oncol. 2008 Aug;33(2):317-23. PMID: 18636152

Sarkar DK, Boyadjieva NI, Chen CP, et al. Cyclic adenosine monophosphate differentiated beta-endorphin neurons promote immune function and prevent prostate cancer growth. Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):9105-10. PMID: 18562281

Zagon I, Donahue RN, Rogosnitzky M, et al. Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. Exp Biol Med (Maywood). 2008 Aug;233(8):968-79. PMID: 18480416

Zagon IS, Rahn KA, McLaughlin PJ. Opioids and migration, chemotaxis, invasion, and adhesion of human cancer cells. Neuropeptides. 2007 Dec;41(6):441-52. PMID: 17910895

Zagon IS, Verderame MF, Hankins J, et al. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells. Int J Oncol. 2007 Apr;30(4):775-83. PMID: 17332915

McLaughlin PJ, Verderame MF, Hankins JL, et al. Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck. Int J Mol Med. 2007 Mar;19(3):421-8. PMID: 17273790

McLaughlin PJ, Zagon IS. Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor. Int J Oncol. 2006 Jun;28(6):1577-83. PMID: 16685459

Zagon IS, Jaglowski JR, Verderame MF, et al. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2005 Nov;56(5):510-20. PMID: 15947928

Zagon IS, McLaughlin PJ. Opioids and differentiation in human cancer cells. Neuropeptides. 2005 Oct;39(5):495-505. PMID: 16169076

Jaglowski JR, Zagon IS, Stack BC, et al. Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2005 Jul;56(1):97-104. PMID: 15791460

McLaughlin PJ, Jaglowski JR, Verderame MF, et al. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of paclitaxel and opioid growth factor. Int J Oncol. 2005 Mar;26(3):809-16. PMID: 15703840

Zagon IS, McLaughlin PJ. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells. Int J Oncol. 2004 Jun;24(6):1443-8. PMID: 15138586

Smith JP, Conter RL, Bingaman SI, et al. Treatment of advanced pancreatic cancer with opioid growth factor: phase I. Anticancer Drugs. 2004 Mar;15(3):203-9. PMID: 15014352

McLaughlin PJ, Levin RJ, Zagon IS. Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude mice. Cancer Lett. 2003 Sep 25;199(2):209-17. PMID: 12969794

McLaughlin PJ, Stack BC, Levin RJ, et al. Defects in the opioid growth factor receptor in human squamous cell carcinoma of the head and neck. Cancer. 2003 Apr 1;97(7):1701-10. PMID: 12655527

Blebea J, Mazo JE, Kihara TK, et al. Opioid growth factor modulates angiogenesis. J Vasc Surg. 2000 Aug;32(2):364-73. PMID: 10917997

McLaughlin PJ, Levin RJ, Zagon IS. The opioid growth factor receptor in human head and neck squamous cell carcinoma. Int J Mol Med. 2000 Feb;5(2):191-6. PMID: 10639600

Bisignani GJ, McLaughlin PJ, Ordille SD, et al. Human renal cell cancer proliferation in tissue culture is tonically inhibited by opioid growth factor. J Urol. 1999 Dec;162(6):2186-91. PMID: 10569617

McLaughlin PJ, Levin RJ, Zagon IS. Regulation of human head and neck squamous cell carcinoma growth in tissue culture by opioid growth factor. Int J Oncol. 1999 May;14(5):991-8. PMID: 10200353

Zagon IS, Smith JP, McLaughlin PJ. Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor. Int J Oncol. 1999 Mar;14(3):577-84.PMID: 10024694

McLaughlin PJ, Zagon IS, Skitzki J. Human neuroblastoma cell growth in tissue culture is regulated by opioid growth factor. Int J Oncol. 1999 Feb;14(2):373-80. PMID: 917516

Levin RJ, Wu Y, McLaughlin PJ, et al. Expression of the opioid growth factor, [Met5]-enkephalin, and the zeta opioid receptor in head and neck squamous cell carcinoma. Laryngoscope. 1997 Mar;107(3):335-9. PMID: 9121309

Zagon IS, Hytrek SD, Smith JP, et al. Opioid growth factor (OGF) inhibits human pancreatic cancer transplanted into nude mice. Cancer Lett. 1997 Jan 30;112(2):167-75. PMID: 9066724

Zagon IS, Hytrek SD, McLaughlin PJ. Opioid growth factor tonically inhibits human colon cancer cell proliferation in tissue culture. Am J Physiol. 1996 Sep;271(3 Pt 2):R511-8.PMID: 8853370

Zagon IS, Hytrek SD, Lang CM, et al. Opioid growth factor ([Met5]enkephalin) prevents the incidence and retards the growth of human colon cancer. Am J Physiol. 1996 Sep;271(3 Pt 2):R780-6. PMID: 885340

Hytrek SD, McLaughlin PJ, Lang CM, et al. Inhibition of human colon cancer by intermittent opioid receptor blockade with naltrexone. Cancer Lett. 1996 Mar 29;101(2):159-64.PMID: 8620464

Murgo AJ. Modulation of murine melanoma growth by naloxone. Cancer Lett. 1989 Feb;44(2):137-42. PMID: 2920373

Zagon IS, McLaughlin PJ. Opioid antagonist modulation of murine neuroblastoma: a profile of cell proliferation and opioid peptides and receptors. Brain Res. 1989 Feb 20;480(1-2):16-28. PMID: 2540873

Zagon IS, McLaughlin P. Endogenous opioids and the growth regulation of a neural tumor. Life Sci. 1988;43(16):1313-8. PMID: 2845218

Faith RE, Murgo AJ. Inhibition of pulmonary metastases and enhancement of natural killer cell activity by methionine-enkephalin. Brain Behav Immun. 1988 Jun;2(2):114-22.PMID: 3233355

Zagon IS, McLaughlin PJ, Goodman SR, et al. Opioid receptors and endogenous opioids in diverse human and animal cancers. J Natl Cancer Inst. 1987 Nov;79(5):1059-65. PMID: 2824913

McLaughlin PJ, Zagon IS. Modulation of human neuroblastoma transplanted into nude mice by endogenous opioid systems. Life Sci. 1987 Sep 21;41(12):1465-72. PMID: 3041143

Murgo AJ. Inhibition of B16-BL6 melanoma growth in mice by methionine-enkephalin. J Natl Cancer Inst. 1985 Aug;75(2):341-4. PMID: 3860686

Zagon IS, McLaughlin PJ. Duration of opiate receptor blockade determines tumorigenic response in mice with neuroblastoma: a role for endogenous opioid systems in cancer. Life Sci. 1984 Jul 23;35(4):409-16. PMID: 6087062

Froelich CJ, Bankhurst AD. The effect of beta-endorphin on natural cytotoxicity and antibody dependent cellular cytotoxicity. Life Sci. 1984 Jul 16;35(3):261-5. PMID: 6087056

Zagon IS, McLaughlin PJ. Opioid antagonists inhibit the growth of metastatic murine neuroblastoma. Cancer Lett. 1983 Nov;21(1):89-94. PMID: 6640516

Zagon IS, McLaughlin PJ. Naltrexone modulates tumor response in mice with neuroblastoma. Science. 1983 Aug 12;221(4611):671-3. PMID: 6867737

Mathews PM, Froelich CJ, Sibbitt WL Jr., et al. Enhancement of natural cytotoxicity by beta-endorphin. J Immunol. 1983 Apr;130(4):1658-62. PMID: 6300232

HIV and other infections

Steele AD, Henderson EE, Rogers TJ. Mu-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication. Virology. 2003 Apr 25;309(1):99-107. PMID: 12726730

Gekker G, Lokensgard JR, Peterson PK. Naltrexone potentiates anti-HIV-1 activity of antiretroviral drugs in CD4+ lymphocyte cultures. Drug Alcohol Depend. 2001 Nov 1;64(3):257-63. PMID: 11672940

Sharp BM, Gekker G, Li MD, et al. Delta-opioid suppression of human immunodeficiency virus-1 expression in T cells (Jurkat). Biochem Pharmacol. 1998 Aug 1;56(3):289-92.PMID: 9744564

Risdahl JM, Khanna KV, Peterson PK, et al. Opiates and infection. J Neuroimmunol. 1998 Mar 15;83(1-2):4-18. PMID: 9610668

Arnalich F, Martinez P, Hernanz A, et al. Altered concentrations of appetite regulators may contribute to the development and maintenance of HIV-associated wasting. AIDS. 1997 Jul 15;11(9):1129-34. PMID: 9233460

Chao CC, Gekker G, Hu S, et al. kappa opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression. Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):8051-6. PMID: 8755601

Spinazzola F, Barletta C, Demartino G, et al. Beta-endorphins ACTH and cortisol in CSF and plasma of HIV infected patients. Riv Eur Sci Med Farmacol. 1995 Sep-Oct;17(5):161-5. PMID: 8766783

Bruno RL, Sapolsky R, Zimmerman JR, et al. Pathophysiology of a central cause of post-polio fatigue. Ann N Y Acad Sci. 1995 May 25;753:257-75. PMID: 7611635

Zagon IS, McLaughlin PJ. An opioid growth factor regulates the replication of microorganisms. Life Sci. 1992;50(16):1179-87. PMID: 1313136

Plotnikoff N, Wybran J. Methionine-enkephalin shows promise in reducing HIV in blood. Am Fam Physician. 1989 Sep;40(3):234. PMID: 2773759

Autoimmune diseases

Zagon IS, McLaughlin PJ. Targeting opioid signaling in Crohn's disease: new therapeutic pathways. Expert Rev Gastroenterol Hepatol. 2011 Oct;5(5):555-8. PMID: 21910569

Siddique I, Khan I. Mechanism of regulation of Na-H exchanger in inflammatory bowel disease: role of TLR-4 signaling mechanism. Dig Dis Sci. 2011 Jun;56(6):1656-62. PMID: 21221801

Zagon IS, Donahue RN, Bonneau RH, et al. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases. Immunobiology. 2011 May;216(5):579-90. PMID: 20965606

Zagon IS, Donahue RN, Bonneau RH, et al. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases. Immunobiology. 2011 Jan-Feb;216(1-2):173-83. PMID: 20598772

McNearney TA, Sluka KA, Ahn C, et al. Plasma endogenous enkephalin levels in early systemic sclerosis: clinical and laboratory associations. Clin Exp Rheumatol. 2010 Mar-Apr;28(2 Suppl 58):S7-11. PMID: 20576209

Zagon IS, Rahn KA, Bonneau RH, et al. Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis. Brain Res. 2010 Jan 15;1310:154-61. PMID: 19931226

Marks DJ, Harbord MW, MacAllister R, et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet. 2006 Feb 25;367(9511):668-78. PMID: 165034?5

Philippe D, Dubuquoy L, Groux H. Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. J Clin Invest. 2003 May;111(9):1329-38. PMID: 12727924

Gironi M, Furlan R, Rovaris M, et al. Beta endorphin concentrations in PBMC of patients with different clinical phenotypes of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):495-7. PMID: 12640071

Sacerdote P, Lechner O, Sidman C. Hypothalamic beta-endorphin concentrations are decreased in animals models of autoimmune disease. J Neuroimmunol. 1999 Jun 1;97(1-2):129-33. PMID: 10408966

Wiedermann CJ, Sacerdote P, Propst A, et al. Decreased beta-endorphin content in peripheral blood mononuclear leukocytes from patients with Crohn's disease. Brain Behav Immun. 1994 Sep;8(3):261-9. PMID: 7865897

CFS/ME etc

Pall ML. Nitric oxide synthase partial uncoupling as a key switching mechanism for the NO/ONOO- cycle. Med Hypotheses. 2007 Apr 18. PMID: 17448611

Conti F, Pittoni V, Sacerdote P. Decreased immunoreactive beta-endorphin in mononuclear leucocytes from patients with chronic fatigue syndrome. Clin Exp Rheumatol. 1998 Nov-Dec;16(6):729-32. PMID: 9844768

Whiteside TL, Friberg D. Natural killer cells and natural killer cell activity in chronic fatigue syndrome. Am J Med. 1998 Sep 28;105(3A):27S-34S. PMID: 9790479

Immune system in general

Davis RL, Buck DJ, Saffarian N, et al. The opioid antagonist, beta-funaltrexamine, inhibits chemokine expression in human astroglial cells. J Neuroimmunol. 2007 May;186(1-2):141-9. PMID: 17475341

Buckley RH. Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med. 2000 Nov 2;343(18):1313-24. PMID: 11058677

Roy S, Loh HH. Effects of opioids on the immune system. Neurochem Res. 1996 Nov;21(11):1375-86. PMID: 8947928

Hsueh CM, Chen SF, Ghanta VK, et al. Expression of the conditioned NK cell activity is beta-endorphin dependent. Brain Res. 1995 Apr 24;678(1-2):76-82. PMID: 7620901

Makman MH. Morphine receptors in immunocytes and neurons. Adv Neuroimmunol. 1994;4(2):69-82. PMID: 7952830

Puente J, Maturana P, Miranda D, et al. Enhancement of human natural killer cell activity by opioid peptides: similar response to methionine-enkephalin and beta-endorphin. Brain Behav Immun. 1992 Mar;6(1):32-9. PMID: 1571602

Bhargava HN. Opioid peptides, receptors, and immune function. NIDA Res Monogr. 1990;96:220-33. PMID: 2172824

Maestroni GJ, Conti A. Beta-endorphin and dynorphin mimic the circadian immunoenhancing and anti-stress effects of melatonin. Int J Immunopharmacol. 1989;11(4):333-40.PMID: 2570759

Faith RE, Liang HJ, Plotnikoff NP, et al. Neuroimmunomodulation with enkephalins: in vitro enhancement of natural killer cell activity in peripheral blood lymphocytes from cancer patients. Nat Immun Cell Growth Regul. 1987;6(2):88-98. PMID: 3600678

Wybran J, Schandene L, Van Vooren JP, et al. Immunologic properties of methionine-enkephalin, and therapeutic implications in AIDS, ARC, and cancer. Ann N Y Acad Sci. 1987;496:108-14. PMID: 3496822

Faith RE, Murgo AJ, Clinkscales CW, et al. Enhancement of host resistance to viral and tumor challenge by treatment with methionine-enkephalin. Ann N Y Acad Sci. 1987;496:137-45. PMID: 3474965

Sharp BM, Tsukayama DT, Gekker G, et al. Beta-endorphin stimulates human polymorphonuclear leukocyte superoxide production via a stereoselective opiate receptor. J Pharmacol Exp Ther. 1987 Aug;242(2):579-82. PMID: 3039121

Brown SL, Van Epps DE. Opioid peptides modulate production of interferon gamma by human mononuclear cells. Cell Immunol. 1986 Nov;103(1):19-26. PMID: 3026654

Plotnikoff NP, Murgo AJ, Miller GC. Enkephalins: immunomodulators. Fed Proc. 1985 Jan;44(1 Pt 1):118-22. PMID: 3967769

Faith RE, Liang HJ, Murgo AJ, et al. Neuroimmunomodulation with enkephalins: enhancement of human natural killer (NK) cell activity in vitro. Clin Immunol Immunopathol. 1984 Jun;31(3):412-8. PMID: 6713744

Wound healing

McLaughlin PJ, Pothering CA, Immonen JA, et al. Topical treatment with the opioid antagonist naltrexone facilitates closure of full-thickness wounds in diabetic rats. Exp Biol Med (Maywood). 2011 Oct 1;236(10):1122-32. PMID: 21917593

Bigliardi PL, Sumanovski LT, Buchner S, et al. Different expression of mu-opiate receptor in chronic and acute wounds and the effect of beta-endorphin on transforming growth factor beta type II receptor and cytokeratin 16 expression. J Invest Dermatol. 2003 Jan;120(1):145-52. PMID: 12535211

Zagon IS, Verderame MF, Allen SS. Cloning, sequencing, expression and function of a cDNA encoding a receptor for the opioid growth factor, [Met(5)]enkephalin. Brain Res. 1999 Dec 4;849(1-2):147-54. PMID: 10592296

Neuroprotection

Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007 Jan;8(1):57-69. PMID: 17180163

Zhang W, Hong JS, Kim HC, et al. Morphinan neuroprotection: new insight into the therapy of neurodegeneration. Crit Rev Neurobiol. 2004;16(4):271-302. PMID: 15862109

Hill MP, Hille CJ, Brotchie JM. Delta-opioid receptor agonists as a therapeutic approach in Parkinson's disease. Drug News Perspect. 2000 Jun;13(5):261-8. PMID: 12937640

Sandyk R, Gillman MA. Opioid hypofunction in Parkinson's disease. Med Hypotheses. 1985 Feb;16(2):179-82. PMID: 2581117

Psychiatric

Zangen A, Nakash R, Roth-Deri I, et al. Impaired release of beta-endorphin in response to serotonin in a rat model of depression. Neuroscience. 2002;110(3):389-93. PMID: 11906780

Bernstein HG, Krell D, Emrich HM, et al. Fewer beta-endorphin expressing arcuate nucleus neurons and reduced beta-endorphinergic innervation of paraventricular neurons in schizophrenics and patients with depression. Cell Mol Biol (Noisy-le-grand). 2002;48 Online Pub:OL259-65. PMID: 12643442

Darko DF, Irwin MR, Risch SC. Plasma beta-endorphin and natural killer cell activity in major depression: a preliminary study. Psychiatry Res. 1992 Aug;43(2):111-9. PMID: 1410068

Galard R, Gallart J, Arguello JM, et al. Plasma levels of beta-endorphin, cortisol, prolactin and growth hormone in depressed patients. Acta Psychiatr Scand. 1988 Aug;78(2):230-3. PMID: 2975911

Gerner RH, Catlin DH, Gorelick DA, et al. beta-Endorphin. Intravenous infusion causes behavioral change in psychiatric inpatients. Arch Gen Psychiatry. 1980 Jun;37(6):642-7.PMID: 7387336

Pain

Hutchinson MR, Zhang Y, Brown K, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci. 2008 Jul;28(1):20-9. PMID: 18662331

Cabot PJ, Carter L, Schäfer M, et al. Methionine-enkephalin-and Dynorphin A-release from immune cells and control of inflammatory pain. Pain. 2001 Sep;93(3):207-12. PMID: 11514079

Cabot PJ. Immune-derived opioids and peripheral antinociception. Clin Exp Pharmacol Physiol. 2001 Mar;28(3):230-2. PMID: 11236131

Battistella PA, Bordin A, Cernetti R, et al. beta-endorphin in plasma and monocytes in juvenile headache. Headache. 1996 Feb;36(2):91-4. PMID: 8742680

Leone M, Sacerdote P, D'Amico D, et al. Beta-endorphin levels are reduced in peripheral blood mononuclear cells of cluster headache patients. Cephalalgia. 1993 Dec;13(6):413-6. PMID: 8313456

Leone M, Sacerdote P, D'Amico D, et al. Beta-endorphin concentrations in the peripheral blood mononuclear cells of migraine and tension-type headache patients. Cephalalgia. 1992 Jun;12(3):154-7. PMID: 1298216

Other

Crayton R, Soller W, Mattiasson A, et al. Exogenously administered opioids contract the female rat intrinsic urethral sphincter in vivo. Neurourol Urodyn. 2010 Jun;29(5):777-82. PMID: 19899147

Walters AS, Ondo WG, Zhu W, et al. Does the endogenous opiate system play a role in the Restless Legs Syndrome? A pilot post-mortem study. J Neurol Sci. 2009 Apr 15;279(1-2):62-5. PMID: 19167016

Andjelkov N, Elvenes J, Knutsen G, et al. Beta-endorphin regulation of MAPKs in cultured human articular chondrocytes: MAPK inhibitors prevent the increase of IL-1 beta protein levels during beta-endorphin stimulation. Cell Commun Adhes. 2007 Jan-Feb;14(1):1-8. PMID: 17453826

Plotnikoff NP, Faith RE, Murgo AJ. Methionine enkephalin: a new cytokine--human studies. Clin Immunol Immunopathol. 1997 Feb;82(2):93-101. PMID: 9000477

Vercellini P, Sacerdote P, Panerai AE. Mononuclear cell beta-endorphin concentration in women with and without endometriosis. Obstet Gynecol. 1992 May;79(5 ( Pt 1)):743-6.PMID: 1565359

Nagy JT, Foris G, Paragh G, et al. Possible correction of defective polymorphonuclear cell functions in type-2 diabetes mellitus by met-enkephalin. Ann N Y Acad Sci. 1987;496:166-9. PMID: 3037972

Blum K, Gaskill H, DeLallo L, et al. Methionine enkephalin as a possible neuromodulator of regional cerebral blood flow. Experientia. 1985 Jul 15;41(7):932-3. PMID: 4007131

Unfinished and future studies on LDN

The results of at second fibromyalgia study and a study of LDN for children with Crohn's disease are pending publication. A study of LDN for juvenile fibromyalgia was unfortunately cancelled.

More LDN Web Links

source: http://www.ldners.org/resources.htm

 LowDoseNaltrexone.org  
   
Dr. Bihari's 20 years of clinical experience with LDN for MS, cancer, HIV...

 Worldwide Petition Drive for LDN Research - over 11,000 so far - add your vote!

 UK LDN Research Petition Drive and Interview

 How To Talk to Your Doctor about LDN 

 RemedyFind/RevolutionHealth: Naltrexone 

 LDN Q&A with Dr. Skip Lenz, Pharm.D. F.A.S.C.P.

 LDN Patient Tracking Database for all diseases
, started 2009. Post your results!
   MS survey matches SammyJo's 2004 survey for comparison.
   This is not "just anecdotes" - this is Patient Based Evidence!

 Project LDN: Funding Clinical Trials - and organizer of the USA LDN Conferences.

LDN for MS

 MS Resource Centre
   LDN info for those in the UK, and reports from those on LDN 
 

 PatientsLikeMe  SammyJo Profile
   Resource for tracking your MS, and many patients using LDN.

 Neuro Immune Disease - Dr. Gihooly's program for MS, Chronic Fatique, ME & Fibromyaligia

 MS Naltrexone Information by The Compounder, Dr. Larry Frieders, R. Ph.

 Crystal's MS, TM and LDN Website
   Contact Crystal for a list of doctors who prescribe LDN.

 "Up the Creek with a Paddle" 
   A Book About How to Beat MS and Many Autoimmune Disorders with LDN 


 
LDN Research Trust 
   Fund raising for a clinical trial of LDN against MS
 

 
The Mystery Journey ~Multiple Sclerosis an LDN user's story & LDN info

 
Polish Language LDN Site

 Italian Language LDN Site

 Julie's Low Dose Naltrexone Journal - Julie Stachowiak, Ph.D., About.com
 

LDN Discussion Forums

Patient's supporting each other is how we have learned to utilize LDN.

 Yahoo Discussion Group: lowdosenaltrexone  
   Large discussion group, over 4000 members.

 Yahoo Group: LDN_Information - Extensive files collection on LDN research.

 Yahoo Group LDN_Users - Support group, talk to others using LDN. 
   Started by Crystal, who mainatains the MS, TM and LDN Website.

 Yahoo Discussion Group: MSWatchers 

 This is MS: Unbiased MS Community 
   An easy to understand explanation for LDN & MS, and Forum

 Histamine, LDN & Alternative MS Therapies  - Earliest LDN forum.

 LDN_4_Cancer - LDN and cancer yahoo group.

 Hepatitis Children & CAM Alternatives - Discussion forum including LDN.

 Healing Parkinsons - Destiny's discussion group on LDN & other alternatives for PD.

 Neurotalk forum discussion on DM and LDN for Parkinson's (also see Research section)

 Go to NeuroTalk, search LDN and naltrexone to see all the conditions patients are using it for.

 
Low Dose Naltrexone Forum  - Jump right in, no registration.  

LDN for Conditions other than MS

 All Conditions which LDN may help - at digitalnaturopath.com

 Autism - LDN information from Dr. Jaquelyn McCandless
   Discussion   Powerpoint  Autism-LDN Yahoo Group - check Files section too.
  
 Book    Videos: 20062008

 AHSTA - Alternative Health Solutions for Thyroid Autoimmunity, LDN topics and surveys.

 LDNforFibro - Discussion group of patients using LDN for Fibromyalgia.

 LDNandIBD - Discussion group of patients using LDN for Crohns, Colitis and IBS.

 LDN4cancer - Dee's story & LDN info, including published papers on treating cancer w/ LDN.

 The Mali HIV+ AIDS LDN Initiative, Dr. McCandless

LDN Compounding Pharmacies in Australia

Stenlake Compounding Chemist

Online Address: http://www.stenlake.com.au
Physical Address: Level 1, 76 Spring Street, Bondi Junction NSW AUSTRALIA 2022
Postal Address: PO Box 2109, Bondi Junction NSW AUSTRALIA 1355
Business Hours: 8.45am to 5.15pm Monday to Friday
tel02 9387 3205      
fax 02 9389 3821
info@stenlake.com.au

Patricia Ullmann
Pharmacist In Charge

Overview:

1) LDN is formulated as fast release- unless the doctor specifies long acting on the prescription (and the patient confirms this)
2) LDN fast release is the default where no release rate is specified
3) Irrespective of the condition to be treated, due to their respective densities,we have found that AVICEL is the suitable filler for naltrexone. Lactose as a filler is unsuitable for all patients due to density variation between it and naltrexone PLUS may be unsuitable for autism where some authorities advise against the intake of sugars.
4) We have not had any requests for topical LDN
5) We have repeat clients

Details:

a) Faxed and online prescriptions are accepted and the medication despatched or picked up by the patient after the originals have been presented or posted.
b) Our facilities are purpose built and we follow SOPs with internal checks and balances.
c) We purchase pure Naltrexone powder from Australian licensed fine chemical suppliers, accompanied by Certificates of Analysis. 
d) Filler is usually rice flour unless a special request is made. Rice filler suits celiac patients or most patients with chemical sensitivities.
e) We will prepare instant release or slow release as specified on the prescription.
f) For high turnover products we employ an additional procedure. The raw materials are analysed by HPLC after they have arrived from the supplier.

Finished products are also randomly analysed. This process is time consuming, expensive and requires special expertise, however if volumes of naltrexone sales justified it, we would consider it. This analytical testing exceeds legal requirements for compounding chemists.

The Green Dispensary Compounding Pharmacy
46 Beulah Rd Norwood SA AUSTRALIA 5067
Tel (08) 83637322      
Fax (08) 83637244
acondina@nunet.com.au
http://www.greendispensary.com
Antony Condina -Compounding Pharmacist

Details:

a) We use pure Naltrexone HCl USP grade powder purchased from Professional Compounding Chemists of Australia.
b) We use Avicel HP 105 (Microcrystalline cellulose NF) fill or patients may request acidophilus, lactobacillus as the fill.
c) Our Low Dose Naltrexone formulations are prepared as "fast release".
d) The process employed during compounding involves  a registered pharmacist with post-graduate qualification in pharmaceutical compounding who weighs ingredients used in compounded medications. A highly accurate method of trituration and mixing powders uniformly is used and then encapsulated into capsules.
e) Details can be entered online and capsules can be posted via express post to patients.
f) We are proud of the service we deliver to our patients not only with LDN but other compounded medications.      

Roper & Parry's
Lismore NSW AUSTRALIA
Tel02 6621 4000      

Dallas Parade Chemist                                                                                                                                                                       Customised Compounding, Keperra, Brisbane Qld                                                                                                                 Blaine Wood (co-owner)                                                                                                                                 Compounding:Tel07 3354 3992 (Mon to Fri only)                                                                                                        Pharmacy:Tel07 3351 7600                                                                                                                                                                                                 http://www.compoundingpharmacy.com                                                                                                                                                 Prescriptions: mailto:rx@compoundingpharmacy.com

Amcal Chempro Chemist
Rimmal Jattan
2717 Main Place,
Broadbeach, Queensland, 4218
Tel07 5539 8751      

Dartnell's Pharmacy
cnr Canterbury & Union Roads
Surrey Hills VIC

Cincotta Chemist
185 Merrylands Rd
Merrylands NSW                                                                                                                                         Tel 02 9897 1011      

Macquarie Pharmacy
Shop 1&2 Lachlan St
Macquarie ACT 2614
Ph: (02) 6251 1063      
Fax: (02) 6251 1203
Luke the pharmacist is happy to deal via fax or post.


ADELAIDE COMPOUNDING
WELLNESS FACTOR NUTRITION
WELLNESS FACTOR SKIN INNOVATIONS
PRICELINE PHARMACY FIRLE

Please contact David or Megan on the details below.

Shop 4, 151 Glynburn Road
FIRLE SA 5070
T: (08) 8361 2999
F: (08) 8331 9709
E: formulation@adelaidecompounding.com.au
W: www.adelaidecompounding.com.au

BioPharm Compounding Chemist

Phone: (07) 5555 7505
Fax: (07) 5555 7506

Ground floor
34 High Street,                                                                                                        Southport, Queensland 4215

http://www.compoundingchemist.com.au/

IMPORTANT: Make sure to specify that you do NOT want LDN in a slow-release form. 

Source: http://www.lowdosenaltrexone.org/

Reports have been received from patients that their pharmacies have been supplying a slow-release form  of naltrexone. Pharmacies should be instructed NOT to provide LDN in an "SR" or slow-release or timed-release form. Unless the low dose of naltrexone is in an unaltered form, which permits it to reach a prompt "spike" in the blood stream, its therapeutic effects may be inhibited.

Fillers. Capsules of LDN necessarily contain a substantial percentage of neutral inactive filler. Experiments by the compounding pharmacist, Dr. Skip Lenz, have demonstrated that the use of calcium carbonate as a filler will interfere with absorption of the LDN capsule. Therefore, it is suggested that calcium carbonate filler not be employed in compounding LDN capsules. He recommends either Avicel, lactose (if lactose intolerance is not a problem), or sucrose fillers as useful fast-release fillers.

> IMPORTANT: Make sure to fill your Rx at a compounding pharmacy that has a reputation for consistent reliability in the quality of the LDN it delivers.

The FDA has found a significant error rate in compounded prescriptions produced at randomly selected pharmacies. Dr. Bihari has reported seeing adverse effects from this problem. Please see our report, Reliability Problem With Compounding Pharmacies. Please see the above list of recommended pharmacies for some suggested sources.

What dosage and frequency should my physician prescribe?

LDN has virtually no side effects. Occasionally, during the first week's use of LDN, patients may complain of some difficulty sleeping. This rarely persists after the first week. Should it do so, dosage can be reduced from 4.5mg to 3mg nightly.

> Cautionary warnings:

  1. Because LDN blocks opioid receptors throughout the body for three or four hours, people using medicine that is an opioid agonist, i.e. narcotic medication — such as Ultram (tramadol), morphine, Percocet, Duragesic patch or codeine-containing medication — should not take LDN until such medicine is completely out of one's system. Patients who have become dependant on daily use of narcotic-containing pain medication may require 10 days to 2 weeks of slowly weaning off of such drugs entirely (while first substituting full doses of non-narcotic pain medications) before being able to begin LDN safely.
  2. Those patients who are taking thyroid hormone replacement for a diagnosis of Hashimoto’s thyroiditis with hypothyroidism ought to begin LDN at the lowest range (1.5mg for an adult). Be aware that LDN may lead to a prompt decrease in the autoimmune disorder, which then may require a rapid reduction in the dose of thyroid hormone replacement in order to avoid symptoms of hyperthyroidism.
  3. Full-dose naltrexone (50mg) carries a cautionary warning against its use in those with liver disease. This warning was placed because of adverse liver effects that were found in experiments involving 300mg daily. The 50mg dose does not apparently produce impairment of liver function nor, of course, do the much smaller 3mg and 4.5mg doses.
  4. People who have received organ transplants and who therefore are taking immunosuppressive medication on a permanent basis are cautioned against the use of LDN because it may act to counter the effect of those medications.

Q and A

Q: So what pain reliever non-narcotic, non-codine related will work with LDN?  My doctors do not understand how it works and what to prescribe even during surgical procedures.  Some say I have to go off of it 1-2 weeks prior to medical procedures.  Examples of medications will help. Any help will be appreciated.
Steven

A: LDN can be taken along with any other medication or substance, so long as it is not narcotic-containing. Naltrexone is a pure opioid antagonist and it will block the action of narcotics. Some examples of narcotic-containing drugs are Ultram, morphine, Percocet, Duragesic patch and any codeine-containing medication

A: Analgesics approved for use with LDN include Moxxor, aspirin, Tylenol®, Advil®, Motrin®, Aleve®, Naprosyn®, Ansaid®, Dolobid®, Orudis®, Voltaren®, Feldene®, Mobic®, and the food supplement, DL-Phenylalanine (DLPA). 

DLPA, which is also said to enhancethe effectiveness of LDN, is suggested to be taken twice a day on an empty stomach in doses of 500 mg. It should not, however, be used by people with high blood pressure. 
 
DL-Phenylalanine 500mg 2x's per day Dr. Bihari recommendation

DL-Phenylalanine (DLPA) isan essential amino acid, meaning the body produces this from the diet. DLPA is a mirror image of the amino acid phenylalanine, it shares a lot of the same benefits as phenylalanine, but in the DL form, its properties for controlling pain naturally are truly amazing.

What are the benefits of D-Phenylalanine?

LDN Dosage

The usual adult dosage is 4.5mg taken once daily at night. Because of the rhythms of the body's production of master hormones, LDN is best taken between 9pm and 3am. Most patients take it at bedtime.

Notable exceptions:

  • People who have multiple sclerosis that has led to muscle spasms are advised to use only 3mg daily and to maintain that dosage.
  • For intial dosage of LDN in those patients who have Hashimoto’s thyroiditis with hypothyroidism and who are taking thyroid hormone replacement medication, please read Cautionary Warnings, below.

Rarely, the naltrexone may need to be purchased as a solution — in distilled water -  with 1mg per ml dispensed with a 5ml medicine dropper. If LDN is used in a liquid form, it is important to keep it refrigerated.

The therapeutic dosage range for LDN is from 1.5mg to 4.5mg every night. Dosages below this range are likely to have no effect at all, and dosages above this range are likely to block endorphins for too long a period of time and interfere with its effectiveness.

> IMPORTANT: Make sure to specify that you do NOT want LDN in a slow-release form (see above).

Are there any side effects or cautionary warnings?

> Side effects:

Q and A

Q: So what pain reliever non-narcotic, non-codine related will work with LDN?  My doctors do not understand how it works and what to prescribe even during surgical procedures.  Some say I have to go off of it 1-2 weeks prior to medical procedures.  Examples of medications will help. Any help will be appreciated.
Steven

  • LDN can be taken along with any other medication or substance, so long as it is not narcotic-containing. Naltrexone is a pure opioid antagonist and it will block the action of narcotics. Some examples of narcotic-containing drugs are Ultram, morphine, Percocet, Duragesic patch and any codeine-containing medication
  • Analgesics approved for use with LDN include Moxxor, aspirin, Tylenol®, Advil®, Motrin®, Aleve®, Naprosyn®, Ansaid®, Dolobid®, Orudis®, Voltaren®, Feldene®, Mobic®, and the food supplement, DL-Phenylalanine (DLPA). 
  • Drugs To Avoid When Taking Low Dose Naltrexone

Articles

Low-Dose Naltrexone (LDN): Tricking the Body to Heal Itself

Low Dose Naltrexone: Harnessing the Body's Own Chemistry to Treat Human Ovarian Cancer

http://www.honestmedicine.com/low-dose-naltrexone/




What You Can Do

> Talk to your doctor.

If you are suffering from HIV/AIDS, cancer, or an autoimmune disease, LDN could help. In AIDS and cancer therapy, LDN is often used in conjunction with other medications.

Cancer. Anyone with cancer or a pre-cancerous condition should consider LDN. Many use LDN as a preventive treatment. Post-treatment, others have been using LDN to prevent a recurrence of their cancer. LDN has been shown in many cases to work with virtually incurable cancers such as neuroblastoma, multiple myeloma, and pancreatic cancer.

HIV/AIDS. As an AIDS drug, LDN leads to far fewer side effects than the standard "AIDS cocktail." When used in conjunction with HAART therapies, LDN can boost T-cell populations, prevent disfiguring lipodystrophy, and lower rates of treatment failure.

Do not be afraid to approach your doctors — physicians today are increasingly open to learning about new therapies in development. Tell your doctors about this website, or print out and hand them the information, and let them weigh the evidence.

> Tell others.

If someone you know has HIV/AIDS, cancer, an autoimmune disease, or one of the aforementioned central nervous system disorders, LDN could save them from a great deal of suffering. If they use e-mail, send them the address of this website (www.lowdosenaltrexone.org). Or, print out the site and mail them the information.

> Help spread the word to the media, the medical community, and to developing countries.

Low-dose naltrexone has the potential to reduce the terrible human loss now taking place throughout the globe. It is a drug that could prevent millions of children from becoming AIDS orphans. It is a drug that could be a powerful ally in the war against cancer.

If you or someone you know has connections in the media, the medical community, or to those in developing countries involved in AIDS policy or treatment, please let them know about LDN.


Charles Darwin

Comments